Multitarget stool DNA testing for colorectal-cancer screening.

BACKGROUND An accurate, noninvasive test could improve the effectiveness of colorectal-cancer screening. METHODS We compared a noninvasive, multitarget stool DNA test with a fecal immunochemical test (FIT) in persons at average risk for colorectal cancer. The DNA test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, and β-actin, plus a hemoglobin immunoassay. Results were generated with the use of a logistic-regression algorithm, with values of 183 or more considered to be positive. FIT values of more than 100 ng of hemoglobin per milliliter of buffer were considered to be positive. Tests were processed independently of colonoscopic findings. RESULTS Of the 9989 participants who could be evaluated, 65 (0.7%) had colorectal cancer and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile serrated polyps measuring ≥1 cm in the greatest dimension) on colonoscopy. The sensitivity for detecting colorectal cancer was 92.3% with DNA testing and 73.8% with FIT (P=0.002). The sensitivity for detecting advanced precancerous lesions was 42.4% with DNA testing and 23.8% with FIT (P<0.001). The rate of detection of polyps with high-grade dysplasia was 69.2% with DNA testing and 46.2% with FIT (P=0.004); the rates of detection of serrated sessile polyps measuring 1 cm or more were 42.4% and 5.1%, respectively (P<0.001). Specificities with DNA testing and FIT were 86.6% and 94.9%, respectively, among participants with nonadvanced or negative findings (P<0.001) and 89.8% and 96.4%, respectively, among those with negative results on colonoscopy (P<0.001). The numbers of persons who would need to be screened to detect one cancer were 154 with colonoscopy, 166 with DNA testing, and 208 with FIT. CONCLUSIONS In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results. (Funded by Exact Sciences; ClinicalTrials.gov number, NCT01397747.).

[1]  Amy B. Knudsen,et al.  Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.

[2]  D. Ahlquist,et al.  A Sensitive Method to Quantify Human Long DNA in Stool: Relevance to Colorectal Cancer Screening , 2006, Cancer Epidemiology Biomarkers & Prevention.

[3]  Charles J. Kahi,et al.  Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel , 2012, The American Journal of Gastroenterology.

[4]  Bruce H Fireman,et al.  Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  D. Sargent,et al.  Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia , 2008, Annals of Internal Medicine.

[6]  Charles J. Kahi,et al.  High colonoscopic prevalence of proximal colon serrated polyps in average-risk men and women. , 2012, Gastrointestinal endoscopy.

[7]  D. Lam-Himlin,et al.  Serrated Lesions of the Colorectum: Review and Recommendations From an Expert Panel , 2013 .

[8]  T. Morikawa,et al.  A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. , 2005, Gastroenterology.

[9]  S. Thibodeau,et al.  Aberrantly Methylated Gene Marker Levels in Stool: Effects of Demographic, Exposure, Body Mass, and Other Patient Characteristics , 2012 .

[10]  H. Allawi,et al.  Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  D. Snover,et al.  Piecemeal snare excision of large sessile colon and rectal polyps: is it adequate? , 1984, Gastrointestinal endoscopy.

[12]  D. Lieberman,et al.  Polyp size and advanced histology in patients undergoing colonoscopy screening: implications for CT colonography. , 2008, Gastroenterology.

[13]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[14]  U. Ladabaum,et al.  Comparative Effectiveness and Cost-Effectiveness of Screening Colonoscopy vs. Sigmoidoscopy and Alternative Strategies , 2013, The American Journal of Gastroenterology.

[15]  D. Ahlquist,et al.  DNA integrity as a potential marker for stool-based detection of colorectal cancer. , 2003, Clinical chemistry.

[16]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[17]  P. Maisonneuve,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps. , 2008, Gastroenterology.

[18]  D. Ransohoff,et al.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.

[19]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[20]  C. Klabunde,et al.  Vital Signs: Colorectal Cancer Screening Test Use — United States, 2012 , 2013, MMWR. Morbidity and mortality weekly report.

[21]  Douglas K Rex,et al.  Corrigendum: American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008 , 2009, The American Journal of Gastroenterology.

[22]  E. Shemesh,et al.  Colonoscopic resection of large colonic polyps--a prospective study. , 1997, Israel journal of medical sciences.

[23]  D. Ahlquist.  Molecular detection of colorectal neoplasia. , 2010, Gastroenterology.

[24]  J. V Schönfeld.  [Colonoscopy versus fecal immunochemical testing in colorectal cancer screening]. , 2013, Zeitschrift fur Gastroenterologie.

[25]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[26]  S. Goodman,et al.  Sensitive digital quantification of DNA methylation in clinical samples , 2009, Nature Biotechnology.

[27]  O. Lantieri,et al.  A population-based comparison of immunochemical fecal occult blood tests for colorectal cancer screening. , 2013, Gastroenterology.

[28]  B. Levin,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.

[29]  A. Fendrick,et al.  As tests evolve and costs of cancer care rise: reappraising stool‐based screening for colorectal neoplasia , 2008, Alimentary pharmacology & therapeutics.

[30]  Angela Fagerlin,et al.  Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. , 2012, Archives of internal medicine.

[31]  B. Manns,et al.  Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation , 2010, PLoS medicine.

[32]  W. Lipshutz,et al.  A novel tableted purgative for colonoscopic preparation: efficacy and safety comparisons with Colyte and Fleet Phospho-Soda. , 2000, Gastrointestinal endoscopy.

[33]  Christie Jp.  Colonoscopic excision of large sessile polyps. , 1977 .

[34]  K. Kinzler,et al.  Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. , 2012, Gastroenterology.

[35]  D. Ahlquist,et al.  Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates , 2012, Pathology.

[36]  J. Millholland,et al.  A Simplified, Noninvasive Stool DNA Test for Colorectal Cancer Detection , 2008, The American Journal of Gastroenterology.

[37]  Bernadette Mazurek Melnyk,et al.  Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. , 2008, Annals of internal medicine.